IlluminaXSWX:ILMN -0.79%76 Days Payable is 56.84 as of Mar. 2026, which is 4% below its 10-year median of 59.40. GuruFocus rates XSWX:ILMN with a GF Score™ of 76/100 and a GF Value™ of CHF105.51. The stock has 7 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, Illumina ranks worse than 59.16% on this metric.
Illumina's average Accounts Payable for the
three
months ended in Mar. 2026 was CHF181 Mil. Illumina's Cost of Goods Sold for the
three
months ended in Mar. 2026 was CHF291 Mil.
Hence, Illumina's Days Payable for the
three
months ended in Mar. 2026 was 56.84.
The historical rank and industry rank for Illumina's Days Payable or its related term are showing as below:
XSWX:ILMN'
s Days Payable Range Over the Past 10 Years
Min: 53.24 Med: 59.4 Max: 70.76
Current: 53.24
During the past 13 years, Illumina's highest Days Payable was 70.76. The lowest was 53.24. And the median was 59.40.
XSWX:ILMN's Days Payable is ranked worse than 59.16% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: 68.87
vs XSWX:ILMN: 53.24
Illumina's Days Payable
increased
from Mar. 2025 (54.80) to Mar. 2026 (56.84).
It may suggest that Illuminadelayed paying its suppliers.
Illumina Days Payable Related Terms
Illumina Days Payable Historical Data
* Premium members only.
The historical data trend for Illumina's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ILMN vs MTD, DGX, LH: Days Payable Comparison
For the Diagnostics & Research subindustry, Illumina's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Illumina Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Days Payable distribution charts can be found below:
* The bar in red indicates where Illumina's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Illumina's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Illumina (XSWX:ILMN) has a Days Payable of 56.84 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Illumina and its competitors. This is near median its historical median of 59.40. Over the past decade, Illumina's Days Payable has ranged from 53.24 to 70.76. According to the industry distribution chart, Illumina ranks #113 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 59.2%.
Is Illumina's Days Payable too high?
Illumina's current Days Payable of 56.84 is near median its 10-year median of 59.40. Over the past 10 years, this metric has ranged from a low of 53.24 to a high of 70.76. The Medical Diagnostics & Research industry median Days Payable is 68.87. Illumina's value of 56.84 is 17.5% below this industry median. Based on the distribution chart, Illumina ranks #113 out of 191 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Illumina has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Illumina's Days Payable compare to MTD and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Illumina ranks #113 out of 191 companies for Days Payable. This places Illumina in the lower half of its industry. The industry median Days Payable is 68.87. Illumina's value of 56.84 is 17.5% below this benchmark. Historically, Illumina's own Days Payable has ranged from 53.24 to 70.76 over the past decade. While the company's 10-year median is 59.40 vs. the industry median of 68.87, Illumina has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 68.87, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Illumina's current Days Payable of 56.84 is 17.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Illumina and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 68.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Illumina's current Days Payable is 56.84, which is near median its own 10-year median of 59.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Illumina stock overvalued right now?
Illumina (XSWX:ILMN) has a current Days Payable of 56.84. The stock's GF Value™ is CHF105.51, compared to a current price of CHF143.95 — trading 36.4% above its estimated fair value. The current Days Payable is 56.84, which is near median its 10-year median of 59.40 and 17.5% below the Medical Diagnostics & Research industry median of 68.87. Illumina's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Illumina (XSWX:ILMN), the current Days Payable is 56.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Illumina (XSWX:ILMN) Overvalued in 2026?
Based on GuruFocus' analysis, Illumina stock appears to be overvalued.
The current stock price of CHF143.95 is trading 36.4% above its estimated GF Value™ of CHF105.51.
Key valuation signals for XSWX:ILMN:
Days Payable: 56.84 (near median its 10-year median of 59.40)
GF Value™: CHF105.51 vs. price of CHF143.95 (36.4% above fair value)
Industry Position: 17.5% below the Medical Diagnostics & Research median (#113 of 191)
No single metric tells the full story. See the XSWX:ILMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
76GF Score
Get the complete analysis for XSWX:ILMN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ILMN has been successfully added to your 
